Celebrex may slow colon cancer

Aug 31, 2006

Two U.S. studies say Pfizer's painkiller Celebrex can slow the recurrence of polyps in the colon for those at a higher risk of developing colon cancer.

But they also caution about an increased risk of heart attacks and strokes from the medicine, reports the Wall Street Journal.

The findings of the studies are published in this week's edition of the New England Journal of Medicine. Celebrex is commonly taken to relieve arthritis pain.

An editorial in the medical journal said because of the cardiovascular risk, Celebrex, or its generic version, has "no role" in preventing cancer in those who don't face high risk of colon cancer, the report said. Early testing is recommended for discovering polyps so they can be removed.

A Pfizer expert was quoted as saying the cancer results are encouraging but added, "We do not recommend Celebrex in treating and preventing cancer." He said the medicine, however, remains an important treatment option for arthritis sufferers.

Copyright 2006 by United Press International

Explore further: The artificial pancreas shown to improve the treatment of type 1 diabetes

add to favorites email to friend print save as pdf

Related Stories

When is a drug too risky to stay on the market?

Jun 30, 2010

(AP) -- The arthritis pill Vioxx was withdrawn but menopause hormones were not, even though both were tied to heart risks. A multiple sclerosis medicine was pulled and later allowed back on. So, when is a drug too risky to ...

Can Celebrex prevent cancer-causing colon polyps?

May 13, 2010

Rush University Medical Center is testing whether celecoxib, known by its brand name Celebrex, can help prevent the growth of precancerous polyps that form in the colon, rectum and small intestine of children with an inheritable ...

Recommended for you

Harm from baseball concussions may linger, study finds

52 minutes ago

(HealthDay)—Even after they're cleared to play following a concussion, baseball players' batting skills are worse than normal, which suggests they may not be fully recovered, a new study suggests.

Ebola vaccine promising in first human trials

1 hour ago

Researchers say they are one step closer to developing a viable Ebola vaccine, with a Phase 1 trial showing promising results, but it will still be months at least before it could be used in the field.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.